Pricing Log in Create free account
Friday 6 November 2026 Export PTN’s income statement to Excel — free account

Palatin Technologies, Inc.

PTN Healthcare Biotechnology

Palatin Technologies, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $13.2 million, up 193.6% from fiscal 2024.

Revenue
−14.1%
EPS
+59.3%
Free cash flow
+34.2%

Quarter to June 2026, against a year earlier

5.74 0.28 −4.65%
Market cap
$10.2M
P/E
12.2×
Fwd P/E
0.2×
Dividend yield
—
F-score
n/a
Altman Z
−67.72
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.01
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 40.57%

Capital & Financial Ratios $m

Size
Market Cap 10.17
Revenue ttm 13.19
Net income ttm (8.38)
Free cash flow ttm (13.59)
Net debt Q (7.49)
Valuation
P/E 12.21
Forward P/E 0.16
Price / sales 1.23
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.43
Financial health
Current ratio Q 4.61 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1,473.27)
Growth
Revenue growth Q −14.06% (below 0%: shrinking)
Operating income growth Q −94.64% (below 0%: shrinking)
EPS, this year +26.24% (at or above 15%: strong)
EPS, next year A +2.60%
Revenue, next year A −34.65% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +3.08%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.7×, against a ten-year median of 2.4×; over the ten years it ranged from −453× in 2021 to 451× in 2021.
P/S against its own 10 years 6.95%
10-year low 10-year high
P/B against its own 10 years 31.26%
10-year low 10-year high
EV/Sales against its own 10 years 10.69%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 11 10 3 7
Receivables 3 — 0 0
Inventory 1 — — —
Other — — — —
16 10 3 8
2023 2024 2025 2026
Payables 4 4 7 1
ST’ Debt — — — —
Other 4 1 — —
15 10 8 2

Compound Annual Growth %

10y 5y 3y
Sales 50.83% 156.83% 107.84%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (33.03%) 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −8.50 Actual −9.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY24 −33.00 −26.50 Beat by 6.50
Q1 FY24 −25.50 −19.50 Beat by 6.00
Q2 FY25 −21.00 −6.00 Beat by 15.00
Q3 FY25 −8.50 −9.00 Miss by 0.50

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 4.26 (2.86) (0.37) (1.11) (2.96)
’25 (19.50) (6.00) (9.00) (2.73) (32.17)
’24 (21.39) (28.00) (26.50) (25.50) (101.00)
’23 (43.00) 12.53 (31.50) (45.50) (110.36)
’22 (37.50) (50.00) (37.50) (67.00) (189.50)
’21 (25.00) (50.00) (25.00) (75.00) (175.00)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 9 0 4 0 13
’24 2 2 — 0 4
’23 1 1 1 2 5
’22 0 0 0 1 1
’21 0 0 0 0 0
’20 0 0 — 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (2) (5) (4) (3) (14)
’25 (7) (5) (5) (4) (21)
’24 (6) (10) (9) (6) (31)
’23 (9) (10) (1) (10) (29)
’22 (6) (6) (9) (8) (30)
’21 4 (14) (4) (9) (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (2) (5) (4) (3) (14)
’25 (7) (5) (5) (4) (21)
’24 (6) (11) (9) (6) (32)
’23 (9) (10) (2) (10) (30)
’22 (6) (6) (10) (8) (30)
’21 4 (14) (4) (9) (23)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 45 67 60 0 0 1 5 4 — 13 (12.7%) 9 7 0 (73.3%)
Gross margin, % 100.00 100.00 100.00 100.00 178.37 85.18 91.38 97.83 — 100.00 0.0 pt
EBT (13) 25 36 (22) (34) (36) (29) (30) (17) (8) (4.6%)
EBT margin, % (28.69) 36.92 59.32 (19,005.08) 17,813.63 (2,464.98) (591.54) (662.26) 0.00 (63.54) (34.8) pt
Net income (13) 25 36 (22) (34) (36) (24) (30) (17) (8) (5.0%)
Per share, $
Per share, $ Revenue 303.62 423.56 363.04 0.63 (1.00) 7.69 22.29 15.27 0.00 4.66 (37.1%)
Earnings (87.50) 150.00 212.50 (125.00) (175.00) (189.50) (110.36) (101.00) (32.15) (2.96) (31.4%)
Cash flow 87.45 10.75 (131.14) 220.17 (119.64) (156.75) (134.40) (107.01) (39.60) (4.79) n/m
Capex (0.91) (0.14) (0.22) (0.34) (0.03) (1.37) (1.99) (0.14) 0.00 (0.02) (35.3%)
Free cash flow 86.55 10.60 (131.36) 219.84 (119.67) (158.12) (136.39) (107.16) (39.60) (4.81) n/m
Book value (35.06) 170.13 605.35 427.13 262.29 85.22 (9.09) (0.38) (8.88) 2.37 n/m
Shares, m 0 0 0 0 0 0 0 0 1 3 +38.9%
Valuation, ×
Valuation, × P/E 0.00 8.06 6.41 0.00 0.00 0.00 0.00 0.00 — 22.96 4.2
P/S 1.37 2.89 2.52 1.99 0.00 45.50 4.71 4.37 — 2.31 7.3
P/B 0.00 7.20 2.25 1.50 2.91 4.11 0.00 0.00 — 4.56 2.5
EV/Sales 0.78 2.33 2.04 0.64 (453.04) 25.54 2.48 2.87 — 1.75 (46.1)
EV/FCF 3.53 93.12 (8.39) 0.93 (3.77) (1.24) (0.41) (0.57) — (1.70) 9.1
Cash, $m
Cash, $m Operating cash flow 13 2 (22) 41 (23) (30) (29) (31) (21) (14) n/m
Capex 0 0 0 0 0 0 0 0 — 0 (10.1%)
Free cash flow 13 2 (22) 41 (23) (30) (30) (32) (21) (14) n/m
Balance, $m
Balance, $m Working capital 2 28 100 80 55 18 1 0 (5) 6 +16.5%
Net debt (34) (38) (44) (82) (59) (30) (11) (10) (3) (7) (15.5%)
Shareholders’ equity (5) 27 101 80 50 16 (2) 0 (5) 7 n/m
Returns, %
Returns, % ROA (39.39) 51.54 49.77 (23.63) (44.10) (70.04) (89.01) (207.35) (247.08) (142.11) (102.7) pt
ROIC 0.00 0.00 39.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 117.20 226.63 56.11 (24.82) (51.76) (109.83) (336.46) 2,843.65 708.07 (877.59) (994.8) pt
People
People Employees 22 19 18 20 26 33 34 30 29 25 +1.4%
Revenue/emp, $m 2.03 3.53 3.35 0.01 (0.01) 0.04 0.14 0.15 0.00 0.53 (13.9%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Palatin Technologies, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TVRD Tvardi Therapeutics, Inc. $11.5M — (loss-making) — (loss-making) +20.33% (above 0%: growing) n/m −57.26% (below 0%: shrinking) 100.00% 0.00% Compare
PASG Passage Bio, Inc. $11.1M — (loss-making) — — n/m −59.81% (below 0%: shrinking) 0.00% 0.00% Compare
LSTA Lisata Therapeutics, Inc. $10.7M — (loss-making) — (loss-making) −98.30% (below 0%: shrinking) n/m +33.04% (above 0%: growing) 100.00% 0.00% Compare
GDTC CytoMed Therapeutics Limited $10.4M — (loss-making) — (loss-making) — n/m −27.39% (below 0%: shrinking) 0.00% — Compare
BIVI BioVie Inc. $10.3M — (loss-making) — — n/m +26.50% (above 0%: growing) 0.00% 0.00% Compare
PTN Palatin Technologies, Inc. $10.2M 12.2× 0.2× −14.06% (below 0%: shrinking) n/m +34.21% (above 0%: growing) 100.00% (1,469.35%)
INTS Intensity Therapeutics Inc. $10.1M — (loss-making) — — n/m +4.72% (above 0%: growing) 0.00% 0.00% Compare
AZR Azora Therapeutics, Inc. $9.7M — (loss-making) — — n/m −263.66% (below 0%: shrinking) 0.00% 0.00% Compare
PHIO Phio Pharmaceuticals Corp. $9.3M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −58.67% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $10.4M — — −8.70% — −42.32% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 25 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 738.50k 96.06k 2.07
2024 1.45m 660.99k 28.89
2023 1.30m 283.92k 31.11

Ownership

Directors and executive officers, together 23.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Palatin Technologies, Inc. (PTN) Latest News

29 Sep

Impact 4 · · Moby

28 Sep

Impact 4 · · PR Newswire

6 Aug

Impact 4 ·

18 May

Impact 4 · · PR Newswire

14 May

Impact 3 · · Moby transcript
Impact 3 ·

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · Benzinga transcript
Impact 3 · · PR Newswire

18 Feb

Impact 3 · · Moby

17 Feb

Impact 4 · · GuruFocus.com
Impact 3 · · PR NewswireMotley Fool

13 Nov

Impact 3 · · PR Newswire

12 Nov

Impact 3 · · PR NewswireInsider MonkeyInsider MonkeyBarchartInsider MonkeyReutersMotley FoolMotley Fool

6 Nov

Impact 4 · · PR Newswire
Impact 3 · · PR Newswire

22 Sep

Impact 4 · · PR Newswire

18 Aug

Impact 4 ·
Impact 3 · · pharmaceutical-technology.com

8 Aug

Impact 3 ·

15 Jul

Impact 4 · · PR Newswire

15 May

Impact 4 · · Thomson Reuters StreetEvents transcript
Impact 3 · · GuruFocus.com

10 May

Impact 3 ·

9 May

Impact 4 ·

8 May

Impact 4 · · PR Newswire

7 May

Impact 4 ·
Impact 3 ·
Impact 3 · · PR Newswire

5 May

Impact 4 · · PR Newswire
stockrow.com/PTN · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com